title: Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis.
abstract: BACKGROUND
  The prevalence of autoimmune liver disease (AiLD)-related autoantibodies has not been defined in Chinese patients with primary biliary cirrhosis (PBC) and therefore needs to be characterized.
  
  
  OBJECTIVE
  The purpose of this study was to explore the prevalence of AiLD-related autoantibodies in Chinese patients with PBC.
  
  
  METHODS
  Indirect immunofluorescence was used to detect anti-mitochondrial antibodies (AMA) in the sera from 198 PBC, 44 autoimmune hepatitis (AIH) and 41 non-autoimmune liver disease controls (LDC). ELISA assays were used to test the presence of anti-M2, anti-gp210, anti-sp100, anti-SLA, anti-LC1 and anti-LKM-1 antibodies.
  
  
  RESULTS
  AMA was present in 92.4, 15.9 and 7.3%, respectively, of patients with PBC, AIH and LDC. Anti-M2 was present in 87.4% of the PBC patients, but only in 4.5 and 4.9%, respectively, of AIH and LDC patients. Anti-gp210 and anti-sp100 were detected in 34.3 and 25.8% of PBC, 6.8 and 15.9% of AIH and in 4.9 and 17.1% of LDC patients. Anti-LC1, anti-SLA and anti-LKM-1 were, respectively, present in 1.5, 0.0 and 0.5% of PBC, and 9.1, 11.4 and 2.3% of AIH, and none of LDC. PBC patients that were AMA-positive presented with higher IgM levels but lower CRP levels than negative ones. ALT, TBIL, DBIL, GGT, ALP, and AST were detected at higher levels and ALB at lower levels in PBC positive for anti-gp210 (P < 0.05).
  
  
  CONCLUSIONS
  The prevalence of AiLD-related autoantibodies we provided might help define PBC in China. Anti-sp100 is not a better prognostic marker for Chinese PBC patients compared to anti-gp210. The identification of effective diagnostic biomarkers for AMA-negative PBC patients is still needed.
authors.affiliation: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No.41 Da Mu Cang, Western District, Beijing 100032, People's Republic of China. huchaojun818@sina.com
authors.forename: Chaojun
authors.initials: C
authors.lastname: Hu
authors.forename: Chuiwen
authors.initials: C
authors.lastname: Deng
authors.forename: Guang
authors.initials: G
authors.lastname: Song
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
authors.forename: Shulan
authors.initials: S
authors.lastname: Zhang
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.forename: Fengchun
authors.initials: F
authors.lastname: Zhang
authors.forename: Yongzhe
authors.initials: Y
authors.lastname: Li
mesh_terms: D000328:Adult; D044466:Asian People; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002681:China; D003937:Diagnosis, Differential; D005260:Female; D019693:Hepatitis, Autoimmune / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D001323:Autoantibodies; D015415:Biomarkers